Treatment Approaches for Perinatal Mental Health Flashcards
6 cards from real PSI practice questions. Tap to flip, then mark Knew It or Still Learning โ missed cards come back until you master them.
Read the first 6 Treatment Approaches for Perinatal Mental Health flashcards as text
Which type of therapy is considered a first-line evidence-based treatment for postpartum depression?
Answer: Cognitive Behavioral Therapy (CBT)
CBT is a well-established, evidence-based first-line psychotherapy for postpartum depression and other perinatal mood disorders.
Interpersonal Therapy (IPT) is particularly effective for perinatal depression because it focuses on what?
Answer: Resolving interpersonal conflicts and role transitions related to new parenthood
IPT targets interpersonal issues such as role transitions and relationship conflicts, which are especially relevant triggers for perinatal depression.
When is pharmacological treatment most clearly indicated for postpartum depression?
Answer: When symptoms are moderate to severe or when psychotherapy alone is insufficient
Medication is most clearly indicated when postpartum depression symptoms are moderate to severe or when psychotherapy alone has not provided adequate relief.
Selective Serotonin Reuptake Inhibitors (SSRIs) are often prescribed for postpartum depression because they do what?
Answer: Increase serotonin availability in the brain to improve mood
SSRIs work by increasing serotonin availability in synapses, which helps regulate mood and is effective in treating postpartum depression.
Which SSRI is often considered a preferred choice during breastfeeding due to its low transfer rate into breast milk?
Answer: Sertraline
Sertraline is commonly considered a preferred SSRI during breastfeeding because it has a low transfer rate into breast milk and a strong safety profile.
What is brexanolone (Zulresso) and why is it significant in postpartum depression treatment?
Answer: The first FDA-approved medication specifically indicated for postpartum depression
Brexanolone (Zulresso) was the first medication specifically FDA-approved for postpartum depression, targeting neurosteroid pathways involved in its onset.